Jeil Pharmaceutical Co Ltd (271980.KS) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · South Korea · ISIN KR7271980005
Jeil Pharmaceutical Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 704.54 bn KRW | 567.24 bn KRW |
| Gross profit | 177.49 bn KRW | 212.90 bn KRW |
| Operating income | -18.55 bn KRW | 21.00 bn KRW |
| EBIT | -21.90 bn KRW | 39.35 bn KRW |
| Net income | -29.97 bn KRW | 23.38 bn KRW |
| Diluted EPS – continuing operations | -2,056.60 KRW | 1,590.22 KRW |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Jeil Pharmaceutical Co Ltd
Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea and internationally. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company exports its products. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, South Korea.
More stocks
- Axon Partners Group S.A. (APG.MC)
- Miwon Holdings Co. Ltd (107590.KS)
- DEFAMA Deutsche Fachmarkt AG (DEF.DE)
- Waldencast plc (WALD)
- PT Murni Sadar Tbk (MTMH.JK)
- LK CHEM (489500.KQ)
- Suzhou Shijing Environmental Technology Co.Ltd. (301030.SZ)
- Shimmick Corp (SHIM)
- Sidus Space Inc. (SIDU)
- Biotalys NV (BTLS.BR)
- Oxford Square Capital Corp. (OXSQ)
- Afyren SAS (ALAFY.PA)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.